American Journal of Cardiology
Volume 101, Issue 7 , Pages 925-929 , 1 April 2008

Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus

  • Nagesh S. Anavekar, MD

      Affiliations

    • Clinical Trials Unit, Austin Health, University of Melbourne, Melbourne, Australia
    • Corresponding Author InformationCorresponding author: Tel: 613-9496-3415; Fax: 613-9496-3418.
    • ,
  • Scott D. Solomon, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
    • ,
  • John J.V. McMurray, MD

      Affiliations

    • Department of Cardiology, Western Infirmary, Glasgow, Scotland
    • ,
  • Aldo Maggioni, MD

      Affiliations

    • Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy
    • ,
  • Jean Lucien Rouleau, MD

      Affiliations

    • Montreal Heart Institute, Montreal, Canada
    • ,
  • Robert Califf, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Harvey White, MD, DSc

      Affiliations

    • Department of Cardiology, Greenlane Hospital, Auckland, New Zealand
    • ,
  • Lars Kober, MD

      Affiliations

    • Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
    • ,
  • Eric Velazquez, MD

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Marc A. Pfeffer, MD, PhD

      Affiliations

    • Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts

Received 24 June 2007 ,Revised 18 November 2007 ,Accepted 18 November 2007.

References 

  1. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–1906
  2. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110:1572–1578
  3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  4. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  6. Chua DY, Bakris GL. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004;22:130–135
  7. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  8. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–927
  9. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–549
  10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  11. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol. 2004;24:147–157
  12. Bakris GL. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004;6:352–356
  13. Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis. 2001;38(Suppl 1):S191–S194
  14. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003;16(suppl):7S–12S
  15. McCullough PA, Bakris GL, Owen WF, Klassen PS, Califf RM. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004;148:243–251
  16. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362
  17. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens. 2002;15:1101–1108

PII: S0002-9149(07)02317-X

doi: 10.1016/j.amjcard.2007.11.037

American Journal of Cardiology
Volume 101, Issue 7 , Pages 925-929 , 1 April 2008

Article Tools

* Image Usage & Resolution